Brian T. Hill MD, PhD
Disclosures
Hill reports research funding from and/or consulting roles with AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Genentech and Gilead Sciences/Kite Pharma.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The unmet needs in mantle cell lymphoma, I think, are couplefold. One is that we know at the time of diagnosis, there are some really high-risk features that probably warrant some approach other than standard chemoimmunotherapy. So for instance, blastoid variant with or without TP53 mutation is often associated with an aggressive clinical course and probably warrants a non-chemotherapy approach. One such regimen that's used and very active in the TP53-mutation-containing patients with mantle cell lymphoma is the so-called BOVIN regimen, which is on national guidelines, which includes zanubrutinib (Brukinsa, BeiGene), obinutuzumab (Gazyva, Genentech) and venetoclax (Venclexta; AbbVie, Genentech), the BCL-2 inhibitor. I think recognizing and testing for TP53 mutation is really important and it's become more really a standard approach in most experienced pathology centers.
